Navigation Links
Foundation Venture Capital Group Invests in Company Developing Plaque-Reducing Dental Hygiene Products

NEW BRUNSWICK, N.J., June 17, 2011 /PRNewswire-USNewswire/ -- Affineti Biologics has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG) to advance its research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine.

According to James M. Golubieski, president of FVCG, the company invested in Affineti because positive results from studies for anti-caries and periodontal therapy look promising in their ability to affect plaque reduction, influencing dental hygiene and systemic medicine.

Affineti founder Dr. Daniel Fine, also a professor and chair, Department of Oral Biology at UMDNJ-New Jersey Dental School, believes the development of products based on his research will prove more effective than others currently available.

His group uses biological principals to create hybrid or fusion proteins that adhere to tissues with potent but non-toxic antimicrobial effects.  He hopes to use these proteins to deliver effective substances locally, avoiding systemic complications. In the short term, Dr. Fine plans to use these proteins in conditions related to the oral cavity and then expand to include mucosal infections in other sites throughout the body.

"We are focused on anti-caries, periodontal disease therapy and dry mouth treatment," Dr. Fine explained. "Additional testing for yeast and bacterial overgrowth will allow us to bring our product for an effective mouthwash for anti-caries, periodontitis and dry mouth to clinical trials shortly."

In addition to the adverse effect of plaque on dental health, current research supports the idea that dental plaque buildup also increases the risk of cardiovascular disease and stroke.

"The link between gum disease and cardiovascular disease is strong enough for us to consider that Dr. Fine's research will impact health on many levels," said Dr. George F. Heinrich, vice chair and CEO of Foundation Venture Capital Group. "We look forward to helping him reach the clinical trial level."

For more information, contact James M. Golubieski, president of FVCG, at (908) 731-6601 or at

About Foundation Venture Capital Group

Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, was founded in 2006 to invest in commercially viable new start-up companies developing technology by faculty at the University of Medicine and Dentistry of New Jersey. In addition to Affineti, it has invested in:  

  • Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies;
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
  • Durin Technologies, working to develop a blood test to diagnose Alzheimer's disease;
  • Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was recently sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm);
  • Snowdon Pharmaceuticals, a drug discovery company focused on several major therapeutic areas.

SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic, Inc. Launches Best-in-Class Next-Generation Sequencing Test for Nuclear Mitochondrial Disorders at the 2011 United Mitochondrial Disease Foundation Meeting
2. Patient Advocate Foundation Announces Additional Support for Patient Co-Pay Relief Program Serving Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Patients
3. Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinsons Cure
4. SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide
5. Boston Scientific Supports Asthma Awareness Month With Donation to Asthma Foundation
6. Bill & Melinda Gates Foundation Funds Bold Ideas Including Empty Virus Shells to Improve Polio Immunity, Dirt-Charged Cell Phones, and Fertilizer Pellets that Reduce Health Risks
7. Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan
8. Fueling Interventional Radiology Growth: SIR Foundation Announces Navilyst Medical Pledge
9. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
10. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
11. FXB Center Partners With The Merck Company Foundation to Reduce Mother-to-Child HIV Transmission Rates in Botswana
Post Your Comments:
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):